NCT06272916

Brief Summary

This study will be conducted to better comprehend the effect of aminophylline in comparison to magnesium sulphate on preventing and/or treating PDPH.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
630

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 15, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 22, 2024

Completed
8 days until next milestone

Study Start

First participant enrolled

March 1, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

February 22, 2024

Status Verified

February 1, 2024

Enrollment Period

1.1 years

First QC Date

February 15, 2024

Last Update Submit

February 16, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Effect of the study drugs on the incidence and severity of PDPH

    100ml of the prepared study drug intravenously immediately after the baby was delivered and umbilical cord was clamped.

Study Arms (1)

sample size of 630 cases was calculated, divided equally into three groups.

For sample size calculation using Yousefshahi et al. (14) as a reference, a sample size of 630 cases was calculated, divided equally into three groups. This sample size achieves 80% power when the effect size is moderate (=0.12) and using 2 degrees of freedom Chi-Squared test with a significant level of 0.05. Using computer generated randomization program, patients were randomly divided into three equal groups. Group 1: patient received 100 ml IV infusion of normal saline (control group). Group 2: patient received Aminophylline 1.5 mg/kg IV infusion diluted in normal saline with a total volume of 100 ml. Group 3: patient received 50 mg/ kg Magnesium sulfate IV infusion diluted in normal saline with a total volume of 100ml.

Drug: Aminophylline , magnesium sulphate and placebo

Interventions

Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section

sample size of 630 cases was calculated, divided equally into three groups.

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale(Gender-based eligibility)
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

All parturient who underwent cesarean section under spinal anesthesia. * Patients who are willing to participate in the trial gave an informed consent. * ASA physical status II. * The age ranged from 20 to 40. * Body Mass Index (BMI) ranged from 25 to 30 kg/m2.

You may qualify if:

  • All parturient who underwent cesarean section under spinal anesthesia.
  • Patients who are willing to participate in the trial gave an informed consent.
  • ASA physical status II.
  • The age ranged from 20 to 40.
  • Body Mass Index (BMI) ranged from 25 to 30 kg/m2.

You may not qualify if:

  • Patient refusal.
  • Allergy to the studied drugs.
  • Patients with contraindications to spinal anesthesia.
  • Those with past history of chronic headache or recent onset of acute headache were excluded.
  • Women who had multiple punctures (\>2) during the spinal anesthesia procedure were excluded from the study.
  • Patients with advanced decompensated cardiac, renal, hepatic disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Post-Dural Puncture Headache

Interventions

AminophyllineMagnesium Sulfate

Condition Hierarchy (Ancestors)

Headache Disorders, SecondaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

EthylenediaminesDiaminesPolyaminesAminesOrganic ChemicalsTheophyllineXanthinesPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsDrug CombinationsPharmaceutical PreparationsMagnesium CompoundsInorganic ChemicalsSulfatesSulfuric AcidsSulfur AcidsSulfur Compounds

Central Study Contacts

Reham M. Abdelbary

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

February 15, 2024

First Posted

February 22, 2024

Study Start

March 1, 2024

Primary Completion

April 1, 2025

Study Completion

June 1, 2025

Last Updated

February 22, 2024

Record last verified: 2024-02